

RESEARCH

Open Access



Gamma rays excited radioluminescence tomographic imaging

Xuanxuan Zhang¹, Shouping Zhu¹, Yang Li¹, Yonghua Zhan¹, Xueli Chen¹, Fei Kang², Jing Wang² and Xu Cao^{1*}

*Correspondence:

caoxu327@gmail.com

¹ Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education & School of Life Science and Technology, Xidian University, Xi'an 710071, Shaanxi, China

Full list of author information is available at the end of the article

Abstract

Background: Radionuclide-excited luminescence imaging is an optical radionuclide imaging strategy to reveal the distributions of radioluminescent nanophosphors (RLNPs) inside small animals, which uses radioluminescence emitted from RLNPs when excited by high energy rays such as gamma rays generated during the decay of radiotracers used in clinical nuclear medicine imaging. Currently, there is no report of tomographic imaging based on radioluminescence.

Methods: In this paper, we proposed a gamma rays excited radioluminescence tomography (GRLT) to reveal three-dimensional distributions of RLNPs inside a small animal using radioluminescence through image reconstruction from surface measurements of radioluminescent photons using an inverse algorithm. The diffusion equation was employed to model propagations of radioluminescent photons in biological tissues with highly scattering and low absorption characteristics.

Results: Phantom and artificial source-implanted mouse model experiments were employed to test the feasibility of GRLT, and the results demonstrated that the ability of GRLT to reveal the distribution of RLNPs such as $Gd_2O_3:S:Tb$ using the radioluminescent signals when excited by gamma rays produced from ^{99m}Tc .

Conclusions: With the emerging of targeted RLNPs, GRLT can provide new possibilities for in vivo and noninvasive examination of biological processes at cellular levels. Especially, combining with Cerenkov luminescence imaging, GRLT can achieve dual molecular information of RLNPs and nuclides using single optical imaging technology.

Keywords: Radioluminescence imaging, Tomography, Diffusion equation, Image reconstruction

Background

Cerenkov luminescence imaging (CLI) can provide distributions of radiotracers by traditional optical imaging technologies [1–3]. It has been used for measuring tumor burden after chemotherapy administration [4, 5], surgical resection [6, 7], and even clinical studies [8–10]. A tomographic imaging based on Cerenkov luminescence has also been proposed to obtain three dimensional distributions of radiotracers [11–16]. However, CLI is limited by its relatively weak optical intensity and poor penetration [7, 9].

A recently emerged optical radionuclide imaging technique, radionuclide-excited luminescence imaging (RELI), is a potential strategy for improving optical intensity, which uses the radioluminescent signals emitted from radioluminescent nanophosphors (RLNPs) when excited by high energy rays such as gamma rays and beta rays generated




during the decay of radionuclides [17–19]. RELI can surpass the weakness and penetration limitation of CLI and provide a new optical approach for imaging radiotracers used in PET [20]. As an internal activatable molecular imaging, RELI based on europium oxide nanophosphor has been performed to detect tumor lesions [21]. The results demonstrated that RELI can provide strong optical signals with high signal-to-background ratios in early and small tumor detection. Investigators have also performed *in vitro* and *in vivo* imaging of ^{99m}Tc using RELI with scintillating crystals [22]. Similarly, with an ingenious design using scintillator and steel plate, β particles excited RELI was evaluated in imaging of amelanotic and melanotic tumors [23]. Combined with microscopic imaging technology, a radioluminescence microscopy was proposed to visualize ^{18}F -FDG uptake in single living cell [24]. A fiber-optic RELI system with a scintillator was developed for imaging ^{18}F -FDG and fluorescent glucose probes from *in vitro* atherosclerotic plaques [25].

Similarly, X-ray was also used to excite RLNPs in X-ray luminescence imaging (XLI), and the emitted X-ray luminescence was acquired by CCD camera [26]. Tomographic imaging based on X-ray luminescence irradiated by a selective X-ray beam scanning scheme was also reported by Carpenter [27–29]. The proposed x-ray luminescence computed tomography (XLCT) can simultaneously provide 3D molecular and anatomical information. To reduce acquisition time, a focused micrometers size X-ray spot using polycapillary lens [30, 31] and cone beam X-ray [32, 33] were used to excite the imaged object.

Due to the excellent penetration of gamma rays in biological tissues, there is no depth limitation on excitation of RLNPs. Besides, optical intensity of RELI is much higher than that of CLI when radionuclide such as ^{99m}Tc is used as the excitation source. These advantages make it possible for RELI to imaging deep lesions for biological applications. But this photographic imaging of RELI can only provide two-dimensional images of radioluminescent signals on the surface of a small animal, which is difficult to reveal distributions of RLNPs deep in the small animal as a result of high scattering of photons in biological tissues.

In this paper, gamma rays excited radioluminescence tomography (GRLT) is proposed to reconstruct three-dimensional distribution of RLNPs inside a small animal using optical measurements of radioluminescence. This internal excitation by radionuclides for GRLT can markedly decrease noises such as auto-fluorescence or leakage of excitation lights in conventional fluorescence imaging, and result in greater signal-to-background ratios. To obtain a tomographic imaging based on radioluminescence, the diffusion equation was employed to model propagations of radioluminescent photons in biological tissues with highly scattering and low absorption characteristics [34–36]. A tangential planar approach, the Kirchhoff approximation, was used to achieve an analytical formulation of the Green's functions of the diffusion equation [37]. After the discretization of imaged medium, a linear equation can be established to describe the relationship between the flux of the radioluminescent source at internal voxels of the grid and the boundary measurements of radioluminescent photons. Phantom and artificial source-implanted mouse model experiments were implemented to validate the feasibility of GRLT.



Methods

In this work, the used radionuclide ^{99m}Tc was obtained from the Department of Nuclear Medicine, Xijing Hospital, the Fourth Military Medical University (FMMU), which produces pure gamma rays with 140 keV. The used RLNPs was terbium doped $\text{Gd}_2\text{O}_2\text{S}$ ($\text{Gd}_2\text{O}_2\text{S:Tb}$), which was purchased from Shanghai Keyan Phosphor Technology Co. Ltd with the mean size of about 100 nm. $\text{Gd}_2\text{O}_2\text{S:Tb}$ is a common used phosphor material in x-rays photography, which can convert x-rays to visual lights. Nowadays, water-soluble $\text{Gd}_2\text{O}_2\text{S:Tb}$ has been used in small animal imaging [38, 39].

To illustrate the origin of radioluminescent signals, we investigated three situations of 100 μL $\text{Na}^{99m}\text{TcO}_4$ with an activity of 7.4 MBq (200 μCi), $\text{Gd}_2\text{O}_2\text{S:Tb}$ with 10 mg, and a mixture of them. Each of the sample was put into a small plastic container, and imaged by a homemade optical imaging system configured by an EMCCD (iXon3 888, Andor) camera coupled with a focus lens (25 mm f/0.95 s, Schneider) simultaneously. The exposure time and EM gain were set to 5 s and 100, respectively. In Fig. 1a, the left, middle and right are the single ^{99m}Tc , the mixture and the single $\text{Gd}_2\text{O}_2\text{S:Tb}$, respectively. There were strong radioluminescent signals from the mixture, but no signals captured for the single ^{99m}Tc and $\text{Gd}_2\text{O}_2\text{S:Tb}$. It is known that ^{99m}Tc alone emits a weak radioluminescence light and can be detected using IVIS imaging system [40]. The low activity of ^{99m}Tc and short exposure time are the reasons for non-captured signals from ^{99m}Tc .

This implies the radioluminescent signal is mainly produced when $\text{Gd}_2\text{O}_2\text{S:Tb}$ is excited by gamma rays generated during the decay of ^{99m}Tc . Furthermore, the spectrum

of radioluminescence was measured using a fluorescence spectrophotometer (F-4500, Hitachi, Japan). Because the mixture itself can emit optical signals without external excitation, the lamp of fluorescence spectrometer was close when measuring the spectrum. The spectrogram of the radioluminescence of the mixture is shown as in Fig. 1b, and there are three peaks at 490, 545 and 585 nm.

For GRLT radionuclides inside a small animal are used as the internal excitation source, whose distributions are very complex and varying with time. To simplify the model of GRLT, here we just consider the distributions of emitted radioluminescence. To obtain a tomographic imaging based on radioluminescence, the diffusion equation is employed to model propagations of radioluminescent photons in biological tissues with high scattering and low absorption characteristics [34–36]:

$$\begin{cases} -\nabla \cdot [D(r)\nabla\Phi(r)] + \mu_a(r)\Phi(r) = X(r) & r \in \Omega \\ \Phi(r) + 2AD(r)\nabla\Phi(r) \cdot \hat{n} = 0 & r \in \partial\Omega \end{cases} \quad (1)$$

where $\Phi(r)$ is the flux density of radioluminescence, $X(r)$ denotes the unknown radioluminescent yield, μ_a is the absorption coefficient, $D = -1/[3(\mu_a + \mu_s')]$ is the diffusion coefficient, and μ_s' is the reduced scattering coefficient. Ω and $\partial\Omega$ represent the regions of the object and its boundary, respectively. A is a boundary constant representing the refractive index mismatched between tissues and the surrounding medium. Here a tangential planar approach named Kirchhoff approximation can be used to achieve an analytical formulation of the Green's functions of the diffusion equation [37]. After the discretization of the imaged medium, a linear equation can be established to describe the relationship between the flux of the radioluminescent source at internal voxels of the grid and the boundary measurements of radioluminescent photons:


$$WX = \Phi \quad (2)$$

where W is the weight matrix mapping the unknown radioluminescent yield X into the measurable boundary light intensity Φ .

The inverse problem of GRLT is to solve Eq. (2), which is an ill-posed problem. An effective approach to overcome this ill-posedness is to reduce the number of unknowns by using a priori information about permissible source regions [41–43]. In this work, we use the observation vector $u = W^T\Phi$ as a good local approximation to the unknown radioluminescent yield X . Based on the sparsity of GRLT, if the sparsity level of X is N , we can chose N biggest coordinates of the observation vector u as a permissible source region [44]. Finally, a traditional Tikhonov regularization is employed to solve Eq. (2) with a reduced solving domain decided by the permissible source region.

Results and discussion



It is clear that the intensity of radioluminescent signal is related to the activity of radionuclide and the mass of RLNPs. RELI images for the mixtures of $Gd_2O_2S:Tb$ and ^{99m}Tc with different activities was captured and shown in Fig. 2a after a *12 * 12 median filtering*. The intensity of radioluminescent signal is increase with the activity of ^{99m}Tc . The quantitative analysis of RELI images in Fig. 2a was obtained by calculated the mean




intensity in region of interesting (ROI), and was shown in Fig. 2b. The intensity of radioluminescent signal linearly correlates with radioactivity of ^{99m}Tc .

To test the penetration depth of radioluminescent signals, a glass cup of 40 mm in height and 20 mm in diameter filled with 1% intralipid solution was employed as a physical phantom. Absorption and reduced scattering coefficients for the phantom are 0.002 and 1 mm^{-1} , respectively, which are similar with those of biological tissues. A small glass tube filled with $\text{Na}^{99m}\text{TcO}_4$ with an activity of 3.7 MBq ($100 \mu\text{Ci}$) and $10 \text{ mg Gd}_2\text{O}_2\text{S:Tb}$ was used as the radioluminescent target, and fasten on the bottom of the glass cup. RELI images were captured when different volumes of intralipid solution were added into the glass cup to mimic different depths of the radioluminescent target, and results are summarized as Fig. 3. Radioluminescent signals decrease observably with depths of radioluminescent target as shown in RELI images (Fig. 3a). The quantitative analysis of radioluminescent signals is show in Fig. 3b by mean radioluminescence of ROI. The strong scattering of turbid medium severely degrades the resolution of RELI images with increase of depths as shown in Fig. 3c, d.

Phantom and artificial source-implanted mouse model experiments were implemented to validate the feasibility of GRLT. In phantom experiment, a polyoxymethylene made semi-cylinder with 20 mm in diameter and 30 mm in height was used as the phantom to mimic biological tissues. The absorption and scattering coefficients of the phantom were 0.002 and 1 mm^{-1} , respectively. The phantom had a hole drilled along the axial direction with the depth of about 6 mm. The mixture of $100 \mu\text{L Na}^{99m}\text{TcO}_4$ with an activity 3.7 MBq ($100 \mu\text{Ci}$) and $10 \text{ mg Gd}_2\text{O}_2\text{S:Tb}$ was put into a transparent glass capillary tube with an inner diameter of 2 mm and an outer diameter of 3 mm. Then the glass capillary tube to mimic the radioluminescent target was put into the hole of the semi-cylinder phantom.



Radioluminescent signals were captured by our homemade optical imaging system with exposure time of 5 s for EMCCD camera, and the captured radioluminescent image was shown in Fig. 4a. Subsequently, micro-CT scans of the phantom were performed



(50 kVp, 1.0 mA, 360 views with 1° interval). Filtered back-projection method was used to reconstruct micro-CT data of the phantom, which was used to extract the phantom surface for forward modal calculation of GRLT.

The reconstructed images fused with CT images are shown in Fig. 4b, c, which includes 3D volume rendering and 2D sections of the phantom reconstruction. The location of radioluminescent target reconstructed by GRLT visually matches that in CT image, which can accurately locate the radioluminescent target. This phantom result illustrates that GRLT can accurately obtain three-dimensional distributions of RLNPs when excited by gamma rays.

For artificial source-implanted mouse model experiment, the animal was cared for in accordance with a protocol approved by the Fourth Military Medical University Animal Care and Use Committee. A Kunming mouse with abdomen un-haired by depilatory cream was used as the imaged animal. A pseudo tumor was provided by injecting the mixture of 100 μL $\text{Na}^{99\text{m}}\text{TcO}_4$ with an activity 3.7 MBq (100 μCi), 10 mg $\text{Gd}_2\text{O}_2\text{S:Tb}$ and 100 μL matrigel (BD Biosciences, Sparks, MD) into right abdomen of the mouse under general anesthesia by inhalation of 1–2% isoflurane-oxygen. Radioluminescent image and CT projection images of the mouse were acquired using the same parameter settings and procedures as those in the former phantom experiment. There is obvious radioluminescence at the pseudo tumor location with low background noises (Fig. 5a). After getting the surface of the mouse based on CT reconstruction, we constructed a homogeneous diffuse model with absorption and scattering coefficients of 0.002 and 1 mm^{-1} , respectively.

The results of artificial source-implanted mouse model experiment are summarized in Fig. 5, and the 3D volume rendering of GRLT reconstruction is in accordance with CT image (Fig. 5b). Transversal, coronal and sagittal slices of GRLT are shown in Fig. 5c. This result shows the ability of GRLT to recover the RLNPs distributions in biology tissues for a mouse model.

The Cerenkov luminescence is emitted when charged particles generated from radioactive decay of radiotracer propagating in biology tissues. So CLI reveals the distribution of radiotracer, which is similar with PET or SPECT. While in RELI, radiotracer just serves as an internal excitation source to excite RLNPs, and its imaging target is RLNPs but not radiotracer. Cerenkov luminescence is much weaker than that of RELI, so RELI

have much higher sensitivity and signal to noise ratio than those of CLT when tumors have a low uptake of radiotracer, which is helpful for GRLT to detect tumors at early stage or with a low metabolism. However the Gamma rays excited radioluminescence is rather weak compared to fluorescence of many fluorescent probes. To get high enough signal, we used a high concentration of the RLNPs in the artificial source-implanted mouse model experiment. Some brighter RLNPs are helpful for this method in practical application. Another limitation is the higher radiation dose to the subject, due to the long half-life time of radionuclide ^{99m}Tc .

GRLT is an extension of RELI from two dimensions to three dimensions, which can provide distribution of RLNPs deep in biology tissues. This may provide a useful optical method for imaging deep tumors in preclinical studies. Noting that there is no penetration limitation of the internal excitation source due to the excellent penetration ability of gamma rays, but the peak wavelength of emitted radioluminescence for $\text{Gd}_2\text{O}_2\text{S:Tb}$ is 545 nm, which has a poor penetration depth. Using near infrared spectral region RLNPs such as $\text{Gd}_2\text{O}_2\text{S:Eu}$ may improve the imaging depth of GRLT.

This work is a preliminary study of tomographic imaging based on radioluminescence. The experiments have simplified the complex distribution of radiotracer by using a mixture of RLNPs and radiotracers. And the three-dimensional quantification of RLNPs has not been realized in this work, for one thing, we have not acquired water soluble RLNPs, for another thing, how to accurately obtain the distribution of radiotracer should be solved firstly. In the future work, we will try to overcome these problems and perfect this method.

In the artificial source-implanted mouse experiment, we injected the mixture of RLNPs with $\text{Na}^{99m}\text{TcO}_4$ into the mouse, which is different with a real in vivo experiment, because the physiological uptake in a tumor and the background are neglected. In practice we can use targeting RLNPs to trace tumor, and radionuclide to excite the targeted RLNPs.

Conclusion

In conclusion, results of phantom and artificial source-implanted mouse experiments have demonstrated the ability of GRLT to reveal the distribution of RLNPs such as $\text{Gd}_2\text{O}_2\text{S:Tb}$ using the radioluminescent signals when excited by gamma rays produced from ^{99m}Tc . With the emerging of targeted RLNPs, we believe GRLT can provide new possibilities for in vivo and noninvasive examination of biological processes at cellular levels. Especially, combining with Cerenkov luminescence imaging, GRLT can achieve dual molecular information of RLNPs and nuclides using single optical imaging technology.

Abbreviations

RELI: radionuclide-excited luminescence imaging; RLNP: radioluminescent nanophosphor; GRLT: gamma rays excited radioluminescence tomography; CLT: Cerenkov luminescence imaging; ROI: region of interesting; REFT: radiopharmaceutical excited fluorescence tomography.

Authors' contributions

XZ, XC, and SZ designed the research. XZ and XC developed the algorithm and drafted the manuscript. XC, YL, and YZ performed the experiments. XC and SZ revised the manuscript. All authors read and approved the final manuscript.

Author details

¹ Engineering Research Center of Molecular and Neuro Imaging of the Ministry of Education & School of Life Science and Technology, Xidian University, Xi'an 710071, Shaanxi, China. ² Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, Shaanxi, China.

Acknowledgements

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Data availability statement

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Ethics approval and consent to participate

Not applicable.

Funding

This work was supported by the Program of National Natural Science Foundation of China under Grant Nos. 81227901, 81627807, 61405149, 81230033, and 61471279, the Program of the National key Research and Development Program of China under Grant No. 2016YFC0103802.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 20 November 2017 Accepted: 18 April 2018

Published online: 24 April 2018

References

1. Robertson R, Germanos MS, Li C, Mitchell GS, Cherry SR, Silva MD. Optical imaging of Cerenkov light generation from positron-emitting radiotracers. *Phys Med Biol*. 2009;54:N355–65.
2. Spinelli AE, D'Ambrosio D, Calderan L, Marengo M, Sbarbati A, Boschi F. Cerenkov radiation allows in vivo optical imaging of positron emitting radiotracers. *Phys Med Biol*. 2010;55:483.
3. Liu H, Ren G, Miao Z. Molecular optical imaging with radioactive probes. *PLoS ONE*. 2010;5:e9470.
4. Xu Y, Chang E, Liu H, Jiang H, Gambhir SS, Cheng Z. Proof-of-concept study of monitoring cancer drug therapy with Cerenkov luminescence imaging. *J Nucl Med*. 2012;53:312–7.
5. Robertson R, Germanos MS, Manfredi MG, Smith PG, Silva MD. Multimodal imaging with 18F-FDG PET and Cerenkov luminescence imaging after MLN4924 treatment in a human lymphoma xenograft model. *J Nucl Med*. 2011;52:1764–9.
6. Holland JP, Normand G, Ruggiero A, Lewis JS, Grimm J. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. *Mol Imaging*. 2011;10:177–86.
7. Liu H, Carpenter CM, Jiang H. Intraoperative imaging of tumors using Cerenkov luminescence endoscopy: a feasibility experimental study. *J Nucl Med*. 2012;53:1579–84.
8. Spinelli AE, Ferdeghini M, Cavedon C. First human Cerenkovography. *J Biomed Opt*. 2013;18:020502.
9. Thorek DLJ, Riedl CC, Grimm J. Clinical Cerenkov luminescence imaging of 18F-FDG. *J Nucl Med*. 2014;55:95–8.
10. Hu H, Cao X, Kang F. Feasibility study of novel endoscopic Cerenkov luminescence imaging system in detecting and quantifying gastrointestinal disease: first human results. *Eur Radiol*. 2015;25:1814–22.
11. Li C, Mitchell GS, Cherry SR. Cerenkov luminescence tomography for small-animal imaging. *Opt Lett*. 2010;35:1109–11.
12. Hu Z, Liang J, Yang W, Fan W, Li C, Ma X, Chen X, Ma X, Li X, Qu X, Wang J, Cao F, Tian J. Experimental Cerenkov luminescence tomography of the mouse model with SPECT imaging validation. *Opt Express*. 2010;18:24441–50.
13. Hu Z, Ma X, Qu X, Yang W, Liang J, Wang J, Tian J. Three-dimensional noninvasive monitoring iodine-131 uptake in the thyroid using a modified Cerenkov luminescence tomography approach. *PLoS ONE*. 2012;7:e37623.
14. Zhong J, Tian J, Yang X, Qin C. Whole-body Cerenkov luminescence tomography with the finite element SP(3) method. *Ann Biomed Eng*. 2011;39:1728–35.
15. Zhong J, Qin C, Yang X, Zhu S, Zhang X, Tian J. Cerenkov luminescence tomography for in vivo radiopharmaceutical imaging. *Int J Biomed Imaging*. 2011;2011:641618.
16. Spinelli AE, Kuo C, Rice BW, Calandrino R, Marzola P, Sbarbati A, Boschi F. Multispectral Cerenkov luminescence tomography for small animal optical imaging. *Opt Express*. 2011;19:12605–18.
17. Sun C, Pratz G, Carpenter CM, Liu H, Cheng Z, Gambhir SS, Xing L. Synthesis and radioluminescence of PEGylated Eu³⁺-doped nanophosphors as bioimaging probes. *Adv Mater*. 2011;23:H195–9.
18. Carpenter CM, Sun C, Pratz G, Liu H, Cheng Z, Xing L. Radioluminescent nanophosphors enable multiplexed small-animal imaging. *Opt Express*. 2012;20:11598–604.
19. Spinelli AE, Boschi F. Novel biomedical applications of Cerenkov radiation and radioluminescence imaging. *Phys Med*. 2015;31:120–9.

20. Cao X, Chen X, Kang F, Zhan Y, Cao X, Wang J, Liang J, Tian J. Intensity Enhanced Cerenkov luminescence imaging using terbium doped Gd_2O_3S microparticles. *ACS Appl Mater Inter*. 2015;7:11775–82.
21. Hu Z, Qu Y, Wang K, Zhang X, Zha J, Song T, Bao C, Liu H, Wang Z, Wang J, Liu Z, Liu H, Tian J. In vivo nanoparticle mediated radiopharmaceutical excited fluorescence molecular imaging. *Nat Commun*. 2015;30:7560.
22. Boschi F, Spinelli AE, D'Ambrosio D, Calderan L, Marengo M, Sbarbati A. Combined optical and single photon emission imaging: preliminary results. *Phys Med Biol*. 2009;54:L57.
23. King MT, Carpenter CM, Sun C, Ma X, Le QT, Sunwoo JB, Cheng Z, Prax G, Xing L. β -Radioluminescence Imaging: a comparative evaluation with cerenkov luminescence imaging. *J Nucl Med*. 2015;56:1458–64.
24. Prax G, Chen K, Sun C, Martin L, Carpenter CM, Olcott PD, Xing L. Radioluminescence microscopy: measuring the heterogeneous uptake of radiotracers in single living cells. *PLoS ONE*. 2012;7:e46285.
25. Zaman RT, Kosuge H, Prax G, Carpenter C, Xing L, McConnell MV. Fiber-optic system for dual-modality imaging of glucose probes 18F-FDG and 6-NBDG in atherosclerotic plaques. *PLoS ONE*. 2014;9:e108108.
26. Carpenter CM, Sun C, Prax G, Rao R, Xing L. Hybrid x-ray/optical luminescence imaging: characterization of experimental conditions. *Med Phys*. 2010;37:4011–8.
27. Prax G, Carpenter CM, Sun C, Rao RP, Xing L. Tomographic molecular imaging of x-ray-excitabile nanoparticles. *Opt Lett*. 2010;35:3345–7.
28. Li C, Di K, Bec J, Cherry SR. X-ray luminescence optical tomography imaging: experimental studies. *Opt Lett*. 2013;38:2339–41.
29. Zhang W, Zhu D, Lun M, Li C. Multiple pinhole collimator based X-ray luminescence computed tomography. *Biomed Opt Express*. 2016;7:2506–23.
30. Cong W, Pan Z, Filkins RJ, Srivastava AM, Ishaque AN, Stefanov P, Wang G. X-ray micromodulated luminescence tomography in dual-cone geometry. *J Biomed Opt*. 2014;19:076002.
31. Zhang W, Lun MC, Nguyen AAT, Li C. X-ray luminescence computed tomography using a focused x-ray beam. *J Biomed Opt*. 2017;22:116004.
32. Chen D, Zhu S, Yi H, Zhang X, Chen D, Liang J, Tian J. Cone beam X-ray luminescence computed tomography: a feasibility study. *Med Phys*. 2013;40:031111.
33. Zhang G, Liu F, Liu J, Luo J, Xie Y, Bai J, Xing L. Cone beam x-ray luminescence computed tomography based on Bayesian method. *IEEE Trans Med Imaging*. 2017;36:225–35.
34. Zou W, Pan X. Compressed-sensing-based fluorescence molecular tomographic image reconstruction with grouped sources. *Biomed Eng Online*. 2014;13:119.
35. Zhang X, Cao X, Zhu S. Reconstruction of fluorescence molecular tomography with a cosinoidal level set method. *Biomed Eng Online*. 2017;16:86.
36. Arridge AR. Optical tomography in medical imaging. *Inverse Prob*. 1999;15:41–93.
37. Ripoll J, Nieto-Vesperinas M, Weissleder R, Ntziachristos B. Fast analytical approximation for arbitrary geometries in diffuse optical tomography. *Opt Lett*. 2002;27:527–9.
38. Chen H, Moore T, Qi B, Colvin DC, Jelen EK, Hitchcock DA, He J, Mefford OT, Gore JC, Alexis F, Anker JN. Monitoring pH-triggered drug release from radioluminescent nanocapsules with X-ray excited optical luminescence. *ACS Nano*. 2013;7:1178–87.
39. Zhan Y, Ai F, Chen F, Valdovinos HF, Orbay H, Sun H, Liang J, Barnhart TE, Tian J, Cai W. Intrinsically zirconium-89 Labeled Gd_2O_3S : Eu Nanoprobes for in vivo positron emission tomography and gamma-ray-induced radioluminescence imaging. *Small*. 2016;12:2872–6.
40. Spinelli AE, Calandrino R, Meo SL, Sbarbati A, Boschi F. Optical imaging of Tc-99 m-based tracers: in vitro and in vivo results. *J Biomed Opt*. 2011;16:116023.
41. Cong W, Wang G, Kumar G, Liu Y, Jiang M, Wang LV, Hoffman EA, McLennan G, McCray PB, Zabner J, Cong A. Practical reconstruction method for bioluminescence tomography. *Opt Express*. 2005;13:6756–71.
42. He X, Liang J, Qu X, Huang H, Hou Y, Tian J. Truncated total least squares method with a practical truncation parameter choice scheme for bioluminescence tomography inverse problem. *Int J Biomed Imaging*. 2010;2010:291874.
43. Huang H, Qu X, Liang J, He X, Chen X, Yang D, Tian J. A multi-phase level set framework for source reconstruction in bioluminescence tomography. *J Comput Phys*. 2010;229:5246–56.
44. Needell D, Vershynin R. Uniform uncertainty principle and signal recovery via regularized orthogonal matching pursuit. *Found Comput Math*. 2009;9:317–34.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

